LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Thomson, Neil C. (2016)
Publisher: Taylor and Francis
Languages: English
Types: Article
Subjects:

Classified by OpenAIRE into

mesheuropmc: hormones, hormone substitutes, and hormone antagonists
Corticosteroids are the most effective treatment for asthma, but the therapeutic response varies markedly between individuals, with up to one third of patients showing evidence of insensitivity to corticosteroids. This article summarizes information on genetic, environmental and asthma-related factors as well as demographic and pharmacokinetic variables associated with corticosteroid insensitivity in asthma. Molecular mechanisms proposed to explain corticosteroid insensitivity are reviewed including alterations in glucocorticoid receptor subtype, binding and nuclear translocation, increased proinflammatory transcription factors and defective histone acetylation. Current therapies and future interventions that may restore corticosteroid sensitivity in asthma are discussed, including small molecule drugs and biological agents. In the future, biomarkers may be used in the clinic to predict corticosteroid sensitivity in patients with poorly controlled asthma.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 109. Spears M, Donnelly I, Jolly L et al. Effect of low-dose theophylline plus 116. Kobayashi Y, Wada H, Rossios C et al. A novel macrolide/fluoroketolide, 117. Essilfie A-T, Horvat JC, Kim RY et al. Macrolide therapy suppresses key features of 125. Khorasani N, Baker J, Johnson M, Chung KF, Bhavsar PK. Reversal of corticosteroid 127. Humbert M, De Blay F, Garcia G et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase 141. Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor142. Lea S, Plumb J, Metcalfe H et al. The effect of peroxisome proliferator-activated 164. Heaney LG, Djukanovic R, Woodcock A et al. Research in progress: Medical
  • No similar publications.

Share - Bookmark

Cite this article